Abstract

Thymosin Alpha-1 is a component of Thymosin Fraction 5 responsible for restoring immune function in animals lacking thymus glands. It was the original peptide synthesized from the Thymosin Fraction 5. Unlike β thymosins, which are genetically and chemically unrelated, Thymosin α1 is produced as a 28-amino acid peptide fragment from a longer, 113-amino acid precursor,prothymosin alpha. Research has shown it to enhance cell-mediated immunity in experimental animals and research subjects..
Thymosin Alpha-1 is being researched for the treatment of Hepatitis B and C, and it is also approved for inclusion with vaccines to boost the immune response in the treatment of other diseases.

Exhibiting a variety of immune regulating properties, thymosin-alpha-1 induces differentiation of murine T-cell precursors and human thymocytes and the terminal differentiation of functionally immature cord blood lymphocytes and induces production of IL-2, high affinity IL-2 receptors, and B-cell growth factors by peripheral blood mononuclear cells. T-helper and cytotoxic/suppressor T-cell populations are targets of thymosin activity. Thymosin-alpha-1 has been shown to increase the efficiency of antigen presentation by macrophages and to be an endogenous modulator of alpha-thrombin activity.

Specification

Usage

This product is mainly used for the treatment of chronic hepatitis B immune strengthening agent. Thymosin Alpha-1 is being researched for the treatment of Hepatitis B and C, and it is also approved for inclusion with vaccines to boost the immune response in the treatment of other diseases

Application
Thymosin α1 is now approved in 35 under developed or developing countries for the treatment of Hepatitis B and C, and it is also used to boost the immune response in the treatment of other diseases.

Skype&Whatsapp:86 13690838732

Email: ycsales12@ycphar.com